Category: EGFR + (Epidermal Growth Factor Receptor) Lung Cancer

What You Need to Know About Liquid Biopsies

by Janet Freeman-Daily, Founder of ROS1ders and lung cancer patient/activist, and Lecia V. Sequist, MD, MPH, The Landry Family Associate Professor of Medicine, Harvard Medical School The term “liquid biopsy” is appearing with increasing frequency in the news and lung cancer community discussions. Hundreds of presentations about liquid biopsies were offered this spring at major… Read More

Posted by ALCF Staff on August 15th, 2018

Overcoming Targeted-Therapy Resistance

The June 19 Lung Cancer Living Room featured Dr. Collin Blakely, a lung cancer specialist from UCSF, and Teri Kennedy, lung cancer survivor and patient advocate, discussing “overcoming resistance to targeted therapy.”

As Dr. Blakely stated, “The lung cancer field… Read More

Posted by ALCF Staff on June 29th, 2018

FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Genentech’s PDL1 drug approved in the second line setting for people “with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.”’s-Cancer-Immunotherapy-TECENTRIQ®-Atezolizumab

Posted by ALCF Staff on October 18th, 2016

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

ALCMI Study Finds New Targetable Genetic Alteration in NSCLC

The Genomics of Young Lung Cancer (GoYLC) study has identified a unique and targetable new genetic alteration that drives a subset of lung cancer, as reported this month in the prestigious scientific journal, Cancer Discovery. This alteration is a gene fusion, an abnormality whereby a gene fuses with another, and together this gene fusion drives… Read More

Posted by ALCF Staff on August 8th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016

Cancer Patients Value Quality of Life Over Symptom Management

In October at their headquarters in New York City, CancerCare, a national organization that provides free support and financial services to anyone touched by cancer, held a roundtable discussion on “Improving the Quality of Life for Lung Cancer Patients”. It featured key opinion leaders and lung cancer advocates who discussed the importance of an all-inclusive… Read More

Posted by Dr. Guneet Walia on March 10th, 2016

Lung Cancer in Women: Lets do something about it!

Bonnie J. Addario Lung Cancer Foundation partners with the American Lung Association to fund $250,000 on innovative and transformational research to defeat lung cancer in women An unfortunate and often unknown fact is that lung cancer is the leading cancer killer in women, estimated to be the cause of 1 in 4 female cancer deaths… Read More

Posted by Dr. Guneet Walia on February 25th, 2016

Today is World Cancer Day. Here’s how YOU can #BeTheSolution!

Bonnie J. Addario Lung Cancer Foundation Launches $180,000 Crowdsourcing Challenge to Increase Clinical Trial Patient Enrollment. Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd, encouraging innovators from both within and more importantly, outside healthcare… Read More

Posted by Dr. Guneet Walia on February 4th, 2016